Redx Pharma Plc

Biotech initial public offerings in Europe have been as rare as hen’s teeth in the past few years so the news that Swiss antibiotics specialist BioVersys is looking to list has caught the eye. The Bas

Destiny Pharma plc is set to become the latest UK biotech to bid farewell to the London Stock Exchange’s Alternative Investment Market (AIM) and will take the private route to access cash for its lat

The UK's e-Therapeutics plc has become the latest biotech to quit the London Stock Exchange’s Alternative Investment Market (AIM), with CEO Ali Mortazavi slamming the lack of risk the country's inve

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning